Augmented antitumor effect of tumor necrosis factor-α used together with interferon-γ and lovastatin against MmB16 melanoma in mice

W. Feleszko, Adam Giermasz, J. Golab, R. Zagozdzon, W. Lasek, M. Jakobisiak

Research output: Contribution to journalArticle

Abstract

Lovastatin, a drug used in the treatment of hypercholesterolemia was reported previously to exert synergistic antitumor activity in mice, when used together with tumor necrosis factor-α (TNF-α). As interferon-γ (IFN-γ) was also demonstrated previously to synergistically potentiate antitumor activity of TNF-α, we decided to use lovastin together with TNF-α and IFN-γ in treatment of melanoma MmB 16. Statistically significant inhibition of tumor growth was observed in mice treated with combination of all these agents in comparison to each of the remaining experimental groups. The results of this study extend the previous findings of synergistic efficacy of lovastatin and TNF-α and suggest that the effectiveness of local treatment may be augmented by the use of two or more synergistically acting agents in murine tumor models.

Original languageEnglish (US)
Pages (from-to)25-28
Number of pages4
JournalCentral-European Journal of Immunology
Volume21
Issue number1
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Augmented antitumor effect of tumor necrosis factor-α used together with interferon-γ and lovastatin against MmB16 melanoma in mice'. Together they form a unique fingerprint.

  • Cite this